Leveraging AI and ITRS in Drug Discovery for Inflammatory and Cardiovascular Diseases

Abstract

Artificial Intelligence (AI) and Intelligent Translational Research Systems (ITRS) are reshaping drug discovery for inflammatory and cardiovascular diseases by enabling rapid, data-driven identification of novel therapeutic targets and optimization of drug development pipelines. These technologies integrate genomics, proteomics, and clinical data to accelerate translational insights and support personalized treatment strategies. AI models aid in virtual screening, biomarker identification, and adaptive clinical trial designs, reducing time and cost. ITRS further bridge preclinical and clinical domains, enhancing reproducibility and translational relevance. Despite their promise, challenges persist, including algorithmic bias, data privacy concerns, and the need for transparent validation processes. Ethical oversight is essential to ensure fairness and patient safety. Regulatory frameworks must adapt to the evolving digital landscape, emphasizing interoperability, accountability, and real-world applicability.

Ähnliche Arbeiten